Summary

The Coronavirus (COVID-19) company impact report analyses how the pandemic will impact CVS Health Corp’s performance.

CVS Health Corp is better placed than many specialist retailers to cope with the effects of COVID-19, due to the fact that almost all of its physical stores remain operational during lockdown
CVS Health Corp, alongside its competitor Walgreens is better off than many specialist retailers that only sell medicines as they can now upsell those beauty products to customers visiting their stores to buy healthcare products, thereby generating more sales prospects.


Scope

  • Group sales are now forecast to rise 6.0% in 2020, versus 1.6% growth in 2019 and our original 2020 forecast of 4.5% - highlighting how the crisis has in fact aided the company in maintaining its yearly growth.
  • CVS and its main rival Walgreens have both been primary destinations for healthcare shoppers in the US throughout this crisis. The company’s exhaustive online presence is also complementary during the crisis.
  • According to the group’s Q1 2020 results, it registered a heathy 7.7% rise in same store sales within the front of store part of the business (retail pharmacy); which is impressive considering this is an area with which CVS usually struggles.




Reasons To Buy

  • Use our revised 2020 forecast for CVS Health Corp to understand how it will perform this year.
  • Use our charts to review how CVS health Corp’s sales are split by region globally and how these regions have been impacted by COVID-19.
  • Use our in-depth analysis to review how CVS Health Corp has responded to COVID-19 and how this will affect its performance.